Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX053 in GSD III
NCT04990388Phase 2Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of UX053 in Glycogen storage disease type III, sponsored by Ultragenyx Pharmaceutical Inc.. Started Oct 2021; status: terminated.
02
Drugs
UX053
03
Conditions
Glycogen storage disease type III
Beyond the preview
Go deeper on NCT04990388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990388.